期刊文献+

不同剂型布地奈德对呼吸窘迫综合征患儿血气改善及肺功能的影响 被引量:6

Influence of different dosage forms of budesonide on blood gas improvement and lung function in NRDS
暂未订购
导出
摘要 目的分析不同剂型布地奈德联合肺表面活性物质(PS)对新生儿呼吸窘迫综合征(NRDS)患儿支气管肺发育不良及血气的影响。方法选择95例NRDS患儿为研究对象,均给予布地奈德联合PS治疗,根据布地奈德不同剂型将患者随机分为A(PS+布地奈德气雾剂持续喷入,n=32)、B(PS+单剂布地奈德液体剂型,n=31)、C(PS+布地奈德气雾剂单剂喷入,n=32)三组,比较三组患儿治疗后的血气变化及肺发育不良发生情况。结果治疗前,三组患儿pH、二氧化碳分压(PCO_2)、氧合指数(PaO_2/FiO_2)比较差异无统计学意义(P>0.05);治疗后第4天、第6天,三组患儿的pH组间比较无统计学意义(P>0.05),而三组PCO_2和PaO_2/FiO_2指标间差异有统计学意义(P<0.05或0.01),治疗后第4天、第6天,A组的PCO_2、PaO_2/FiO_2指标均优于B组和C组,B组优于C组。A、B、C三组患儿的辅助持续通气时间分别为(4.3±1.4)d、(9.7±3.3)d、(13.9±3.5)d,三组通气时间比较差异有统计学意义(F=50.247,P=0.003)。三组患儿有创机械通气例数、重复使用PS例数、支气管肺发育不良发生率比较差异均有统计学意义(P<0.01),A组和B组患儿改为有创机械通气例数、重复使用PS例数、支气管肺发育不良发生率均低于C组。结论相比于单剂液体剂型和气雾剂单剂方法,气雾剂型布地奈德持续雾化喷入治疗方式可显著改善患儿血气,降低支气管肺发育不良概率,临床疗效显著,值得推广应用。 Objective To analyze the influence of different dosage forms of budesonide combined with pulmonary surfactant(PS)on bronchopulmonary dysplasia and blood gas in neonatal respiratory distress syndrome(NRDS).Methods 95cases of NRDS were selected as research objects,all given budesonide combined with PS.They were randomly divided into group A(PS+budesonide aerosol continuous injection,n=32),group B(PS+single dose of budesonide liquid form,n=31)and group C(PS+single dose injection of budesonide aerosol,n=32)according to different dosage forms of budesonide.And then,the changes of blood gas and the incidence of dysplasia of lung after treatment were compared between the three groups.Results Before treatment,there was no statistically significant difference in pH,PCO2and PaO2/FiO2between the three groups(P>0.05).Difference of pH was not statistically significant at4th and6th day after treatment(P>0.05),but there was statistically significant difference between PCO2and PaO2/FiO2indexes(P<0.05or0.01).4th and6th day after treatment,PCO2and PaO2/FiO2indexes of the group A were significantly better than those of the group B and the group C,and those of the group B were better than those of the group C.The time of assisted continuous ventilation in the group A,the group B and the group C was respectively(4.3±1.4)d,(9.7±3.3)d and(13.9±3.5)d,difference was statistically significant(F=50.247,P=0.003).Difference of the incidence of invasive mechanical ventilation cases,repeated use cases of PS and bronchopulmonary dysplasia in the three groups was statistically significant(P<0.01),and the incidence of the group A and the group B was lower than that of the group C.Conclusion Compared with single dose liquid dosage form and aerosol single agent method,aerosol inhalation of budesonide can significantly improve blood gas and reduce the risk of bronchopulmonary dysplasia in children.The clinical curative effect is remarkable,and thus it is worthy of popularization and application.
作者 廖亮荣 吴学科 高育健 LIAO Liangrong;WU Xueke;GAO Yujian(People’s Hospital of Guigang,Guigang 537100,China)
出处 《右江医学》 2017年第6期703-706,共4页 Chinese Youjiang Medical Journal
  • 相关文献

参考文献6

二级参考文献53

  • 1胡瑞成,徐永健,张珍祥.Surfactant Protein B 1580 Polymorphism Is Associated with Susceptibility to Chronic Obstructive Pulmonary Disease in Chinese Han Population[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2004,24(3):216-218. 被引量:13
  • 2初桂兰,王静,辛玥,郑军,郑荣秀,毕道濯.预防性应用表面活性剂对新生儿呼吸窘迫综合征防治的研究[J].中华医学杂志,2006,86(13):876-880. 被引量:31
  • 3韩玉昆.新生儿呼吸衰竭诊断标准初步方案[J].中华儿科杂志,1987,25:160-161.
  • 4邵晓梅,叶鸿瑁,丘小汕.实用新生儿学[M].4版.北京:人民卫生出版社,2011:21-31.
  • 5王新兴.皮质激素在早产治疗中的应用[J].中华现代妇产科学杂志,2007,4(3):255-256.
  • 6Kuo H T, Lin H C, Tsai C H, et al. A follow up study of preterm infants given budesonide using surfactan* as a vehicle to prevent chronic lung disease in preterm infants[J]. J Pediatr, 2010,156(4) :537-541.
  • 7Nakahara H, Lee S, Sugihara G, et al. Langmuir monolayer of artifi- cial pulmonary surfactant mixtures with an amphiphilic peptide at the air/water interface: comparison of new preparations with surfae- ten (Surfactant TA) [J]. Langmuir, 2008, 24(7): 3370-3379.
  • 8Lukovic D, Plaseneia I, Tabemer FJ, et al. Production and character- isation of recombinant forms of human pulmonary surfactant pro- tein C (SP-C): Slructure and surface activity [J]. Biochim Biophys Acta, 2006, 1758(4): 509-518.
  • 9MuUowney T, Manson D, Kim R, et al. Primary ciliary dyskinesia and neonatal respiratory distress [J]. Pediatrics, 2014, 134(6): 1160-1166.
  • 10Thall PF, Nguyen HQ, Zohar S, et al. Optimizing sedative dose in preterm infants undergoing treatment for respiratory distress syn- drome [J]. JAm Stat Assoc, 2014, 109(507): 931-943.

共引文献132

同被引文献44

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部